Hemab Therapeutics (NASDAQ:COAG) Upgraded to “Hold” at Zacks Research

Hemab Therapeutics (NASDAQ:COAG) was upgraded by equities researchers at Zacks Research to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

Other equities analysts have also issued research reports about the stock. Jefferies Financial Group started coverage on shares of Hemab Therapeutics in a report on Tuesday. They set a “buy” rating and a $39.00 price objective on the stock. Wedbush started coverage on Hemab Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $42.00 price target on the stock. Evercore assumed coverage on Hemab Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $50.00 price objective for the company. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. Finally, The Goldman Sachs Group started coverage on shares of Hemab Therapeutics in a research note on Tuesday. They set a “buy” rating and a $36.00 price target for the company. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $41.75.

Hemab Therapeutics Price Performance

Shares of NASDAQ COAG opened at $28.00 on Wednesday. Hemab Therapeutics has a 1 year low of $23.00 and a 1 year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Insider Buying and Selling at Hemab Therapeutics

In related news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock in a transaction that occurred on Monday, May 4th. The stock was bought at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the completion of the transaction, the director owned 6,149,096 shares in the company, valued at $110,683,728. This represents a 77.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have bought 2,902,872 shares of company stock valued at $53,769,784.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.